培美曲塞联合顺铂一线治疗晚期非小细胞肺癌的临床观察  

The Clinical Observation of Pemetrexed Combined with Cisplatin as the First-Line Regimen in the Treatment of Advanced Non-Small-Cell Lung Cancer

作　　者：程传耀[1] 周文鹏[2] 吴铁成 

机构地区：[1]河南大学淮河医院血液肿瘤内科,河南开封475000 [2]郑州大学第一附属医院肿瘤内科,河南郑州450052 [3]开封市第一人民医院影像科,河南开封475000

出　　处：《肿瘤基础与临床》2011年第4期298-300,共3页journal of basic and clinical oncology

摘　　要：目的评价培美曲塞联合顺铂一线治疗晚期非小细胞肺癌(NSCLC)的临床疗效和毒副反应。方法 48例初治晚期NSCLC接受培美曲塞联合顺铂化疗,接受2个周期化疗后评价临床疗效和毒副反应。结果 48例中,PR 13例,SD 15例,PD 20例,有效率27.08%,临床获益率58.33%。主要毒副反应为骨髓抑制、胃肠道反应和皮肤过敏。结论培美曲塞联合顺铂一线治疗晚期NSCLC疗效可靠,毒副反应轻。Objective To observe the clinical efficacy and toxicities of pemetrexed combined with cisplatin as the first-line regimen in the treatment of advanced non-small-cell lung cancer（NSCLC）.Methods Forty-eight patients with advanced NSCLC received the pemetrexed combined with cisplatin chemotherapy,the clinical efficacy and toxicities were evaluated after 2 cycles of chemotherapy.Results Of all the 48 cases,the 13 cases with PR,the 15 cases with SD,the 20 cases with PD,the effective rate was 27.08%,and the clinical benefit rate was 58.33%.The main toxicities were marrow suppression,gastrointestinal reaction and skin allergy.Conclusion The pemetrexed combined with cisplatin as the first-line regimen in the treatment of advanced NSCLC has reliable efficacy and fewer toxicities.

关 键 词：培美曲塞 顺铂 晚期非小细胞肺癌 化疗 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]